Actuate Therapeutics Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer

Reuters

2025/08/25

Actuate <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer

Actuate Therapeutics Inc. has announced plans for a Phase 1b clinical trial to evaluate the combination of their drug elra with Incyte Corporation's PD-1 inhibitor retifanlimab and modified FOLFIRINOX (mFOLFIRINOX) as frontline therapy for advanced pancreatic adenocarcinoma. This study will be conducted in collaboration with UPMC Hillman Cancer Center and Incyte. The trial aims to explore synergistic opportunities for patients who have not yet received systemic therapy and to assess ways to optimize elraglusib's potential through a complementary multi-agent approach. Results from this trial have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1064578) on August 25, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2562824030"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562824030\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562824030?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-25 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562824030","market":"nz","top_or_hot":-1,"title":"Actuate Therapeutics Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Actuate <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ACTU\">Actuate Therapeutics Inc</a>. has announced plans for a Phase 1b clinical trial to evaluate the combination of their drug elra with Incyte Corporation's PD-1 inhibitor retifanlimab and modified FOLFIRINOX (mFOLFIRINOX) as frontline therapy for advanced pancreatic adenocarcinoma. This study will be conducted in collaboration with UPMC Hillman Cancer Center and Incyte. The trial aims to explore synergistic opportunities for patients who have not yet received systemic therapy and to assess ways to optimize elraglusib's potential through a complementary multi-agent approach. Results from this trial have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1064578) on August 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Actuate Therapeutics Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nActuate Therapeutics Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-25 22:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Actuate <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ACTU\">Actuate Therapeutics Inc</a>. has announced plans for a Phase 1b clinical trial to evaluate the combination of their drug elra with Incyte Corporation's PD-1 inhibitor retifanlimab and modified FOLFIRINOX (mFOLFIRINOX) as frontline therapy for advanced pancreatic adenocarcinoma. This study will be conducted in collaboration with UPMC Hillman Cancer Center and Incyte. The trial aims to explore synergistic opportunities for patients who have not yet received systemic therapy and to assess ways to optimize elraglusib's potential through a complementary multi-agent approach. Results from this trial have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1064578) on August 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票月供概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nNDL1s25yf:1","article_id":"2562824030","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562824030","pubTimestamp":1756130472,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Actuate Therapeutics Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer. Actuate Therapeutics Inc. has announced plans for a Phase 1b clinical trial to evaluate the combination of their drug elra with Incyte Corporation's PD-1 inhibitor retifanlimab and modified FOLFIRINOX  as frontline therapy for advanced pancreatic adenocarcinoma. This study will be conducted in collaboration with UPMC Hillman Cancer Center and Incyte. The trial aims to explore synergistic opportunities for patients who have not yet received systemic therapy and to assess ways to optimize elraglusib's potential through a complementary multi-agent approach. Results from this trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","ACTU":"Actuate Therapeutics Inc","BK4139":"生物科技","BK4532":"文艺复兴科技持仓","INCY":"因塞特医疗","BK4588":"碎股","BK4550":"红杉资本持仓"},"translate_title":"Actuate Therapeutics宣布Elra联合Retifanlimab和mFOLFIRINOX治疗晚期胰腺癌的新1b期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACTU":0.9,"INCY":0.9},"content_text":"Actuate Therapeutics Announces New Phase 1b Trial of Elra in Combination with Retifanlimab and mFOLFIRINOX for Advanced Pancreatic Cancer\n    \n\nActuate Therapeutics Inc. has announced plans for a Phase 1b clinical trial to evaluate the combination of their drug elra with Incyte Corporation's PD-1 inhibitor retifanlimab and modified FOLFIRINOX (mFOLFIRINOX) as frontline therapy for advanced pancreatic adenocarcinoma. This study will be conducted in collaboration with UPMC Hillman Cancer Center and Incyte. The trial aims to explore synergistic opportunities for patients who have not yet received systemic therapy and to assess ways to optimize elraglusib's potential through a complementary multi-agent approach. Results from this trial have not yet been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1064578) on August 25, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}